Know when to pause before a joint procedure

Get quick help for warning signs

New numbness, weak muscles, or loss of bladder control needs quick medical care. So does a joint that won't hold your weight following a fall.

Soreness that keeps worsening at night also deserves a visit soon. Don't assume every new change comes from ordinary joint wear.

Tell your doctor when several joints swell together. You'll need an exam before deciding about any planned procedure.

Bring details that affect safety

The clinician needs to know about blood thinners and bleeding trouble. An infection can also make a planned procedure unsafe.

Mention problems with your immune system, the body's defense against germs. Also name any condition or medicine that weakens that defense.

Take every medicine name, including anything bought without a prescription. You won't have to depend on memory during the visit.

Check cost and follow-up before deciding

Ask whether insurance covers the visit, treatment, and follow-up care. Paying yourself can be hard when the possible relief is unclear.

Get the total price, including follow-up visits, before agreeing to several treatments. Ask what comes next when the joint feels no better.

Keep the clinic phone number nearby after any procedure. If swelling grows fast, don't wait until the next planned visit.

Who needs to pause before treatment? Anyone with warning signs or an unclear cause needs an exam first.

Sources

1. A randomized, double-blind, placebo-controlled trial in a Japanese population tested leukocyte-POOR PRP specifically in mild-to-moderate knee OA WITH joint effusion or bone marrow lesions - i.e. a selected inflammatory phenotype rather than all comers. Recorded here because phenotype selection, not the product, is the most plausible explanation for why PRP trials disagree with one another.

   Yoshioka T, et al. — The Effectiveness of Leukocyte-Poor Platelet-Rich Plasma Injections for Symptomatic Mild to Moderate Osteoarthritis of the Knee With Joint Effusion or Bone Marrow Lesions in a Japanese Population: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.. The American journal of sports medicine, 2024. DOI: 10.1177/03635465241263073.

2. A randomized trial in the New England Journal of Medicine compared physical therapy against intra-articular glucocorticoid injection for knee osteoarthritis and found physical therapy produced better WOMAC outcomes at one year. When a clinic offers an injection, the comparator that matters is not 'nothing' - it is a course of supervised exercise.

   Deyle GD, et al. — Physical Therapy versus Glucocorticoid Injection for Osteoarthritis of the Knee.. The New England journal of medicine, 2020. DOI: 10.1056/NEJMoa1905877.

3. A CDC-led national public health investigation identified culture-confirmed bacterial infections in 20 patients (median age 63) across 8 US states who received umbilical cord blood-derived products marketed as stem cell treatment for pain, osteoarthritis, rheumatoid arthritis and injury. ALL BUT ONE REQUIRED HOSPITALISATION. Of unopened, undistributed product vials sampled, 65% (22 of 34) were contaminated with at least one of 16 bacterial species, mostly enteric; whole-genome sequencing linked an Arizona patient isolate to product administered in Florida.

   Hartnett KP, et al. — Investigation of Bacterial Infections Among Patients Treated With Umbilical Cord Blood-Derived Products Marketed as Stem Cell Therapies.. JAMA network open, 2021. DOI: 10.1001/jamanetworkopen.2021.28615.

4. FDA's guidance on the 21 CFR 1271.10(a) criteria of MINIMAL MANIPULATION and HOMOLOGOUS USE is the rule that decides whether a cell or tissue product may be offered as a lightly-regulated 'section 361' HCT/P or requires full drug approval as a 'section 351' biologic. Docket FDA-2017-D-6146; the revised July 2020 version extended the agency's period of enforcement discretion through 31 May 2021 - which has now expired, so products outside 361 need an approved application or an active IND.

   US Food and Drug Administration, CBER and CDRH — Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use. FDA, 2020.

5. A cross-sectional study contacted 273 of 317 US centres offering direct-to-consumer stem-cell therapy, posing as a 57-year-old man with knee osteoarthritis. The mean advertised price of a unilateral same-day stem-cell knee injection was $5,156 (SD $2,446), and centres claimed a mean clinical efficacy of 82% (SD 9.6%) - a figure with no support in the published evidence. The gap between the quoted number and the trial data is the single most useful thing a patient can be told before a consultation.

   Piuzzi NS, et al. — The Stem-Cell Market for the Treatment of Knee Osteoarthritis: A Patient Perspective.. The journal of knee surgery, 2018. DOI: 10.1055/s-0037-1604443.

6. Medicare's National Coverage Determination covers autologous platelet-rich plasma ONLY for chronic non-healing diabetic, pressure or venous WOUNDS, and only under Coverage with Evidence Development inside an approved clinical research study. There is no Medicare coverage pathway for PRP as a treatment for osteoarthritis or any other joint indication, which is why these injections are quoted as cash prices.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2012.